Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Similar documents
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 68, NO. 21, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

Polymer-Free Stent CX - ISAR

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

PROMUS Element Experience In AMC

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Fractional Flow Reserve Guided PCI versus Medical Therapy in Stable Coronary Disease. FAME 2 Trial

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

egfr > 50 (n = 13,916)

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Vascular Closure Devices Versus Manual Compression After Femoral Artery Access

The presenter does not have any potential conflicts of interest to disclose

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Improved Noninvasive Assessment of Coronary Artery Bypass Grafts With 64-Slice Computed Tomographic Angiography in an Unselected Patient Population

Patient characteristics Intervention Comparison Length of followup

The MAIN-COMPARE Study

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

CVD risk assessment using risk scores in primary and secondary prevention

Massimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

The MAIN-COMPARE Registry

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Exercise treadmill testing is frequently used in clinical practice to

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Clinical Trial Synopsis TL-OPI-516, NCT#

Intervention: How and to which extent is technology helping us?

Predictive Factors for Early Cardiac Events and Angiographic Restenosis After Coronary Stent Placement in Small Coronary Arteries

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index

Cindy L. Grines MD FACC FSCAI

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

Supplementary Table S1: Proportion of missing values presents in the original dataset

Unprotected LM intervention

SUPPLEMENTAL MATERIAL

Σεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική

Patient referral for elective coronary angiography: challenging the current strategy

Importance of the third arterial graft in multiple arterial grafting strategies

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention

FFR in Multivessel Disease

Declaration of conflict of interest. Nothing to disclose

Coronary Artery Disease: Revascularization (Teacher s Guide)

How will new high sensitive troponins affect the criteria?

Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial

Fractional Flow Reserve and the Results of the FAME Study

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

In-Ho Chae. Seoul National University College of Medicine

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

Supplement materials:

Clinical Investigations

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

Management of ST-elevation myocardial infarction Update 2009 Late comers: which options?

FFR Incorporating & Expanding it s use in Clinical Practice

The Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Adults With Diagnosed Diabetes

New Insight about FFR and IVUS MLA

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease

What do the guidelines say?

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

Thyroid Hormone and Coronary Artery Disease: From Clinical Correlations to Prognostic Implications

Alex versus Xience Registry Preliminary report

Do stents deserve the bad press? Mark A. Tulli MD, FACC

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Use of Biomarkers for Detection of Acute Myocardial Infarction

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?

Uric acid and prognosis in angiography-proven coronary artery disease

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Coronary Plaque Sealing: The DEFER Study and more...

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial

Diabetes and Occult Coronary Artery Disease

SUPPLEMENTAL MATERIAL

Belinda Green, Cardiologist, SDHB, 2016

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Title for Paragraph Format Slide

Coronary interventions

Kavitha Yaddanapudi Stony brook University New York

Chapter 4: Cardiovascular Disease in Patients With CKD

Clinical Investigations

DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Clinical Summary. Live Cases I - IX

Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE

Approach to Multi Vessel disease with STEMI

Transcription:

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky, Hans-Ullrich Haase, Albert Schomig, Jürgen Pache, Adnan Kastrati Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der ISAR, Techniche Universität München, Munich, Germany

ABSTRACT Background: The impact of coronary atherosclerotic burden on prognosis and presentation of patients with coronary artery disease (CAD) is unknown. We investigated the association of coronary atherosclerotic burden with clinical outcome and presentation as unstable angina in patients with CAD. Methods: This study included 10647 patients with stable (n=8149) and unstable (n=2498) CAD who underwent percutaneous coronary intervention (PCI). Coronary atherosclerotic burden was assessed by Gensini score. The primary outcome analysis was 1-year mortality. Results: Gensini score was obtained by analysis of 131360 coronary segments. Patients were divided into groups according to quartiles of Gensini score: <13 (1st quartile; n=2650 patients), 13 to <25 (2nd quartile; n=2611 patients), 25 to <53 (3rd quartile; n=2711 patients) and >53 (4th quartile; n=2665 patients). There were 295 deaths during follow-up: 41 deaths in the 1st quartile, 42 deaths in the 2nd quartile, 83 deaths in the 3rd quartile and 129 deaths in the 4th quartile of Gensini score (Kaplan-Meier estimates of 1-year mortality 1.6%, 1.7%, 3.1% and 5.0%, respectively; adjusted hazards ratio [HR]=1.08, 95% confidence interval [CI] 1.02-1.14, P=0.007 for each 20-point increase in Gensini score). Gensini score was an independent correlate of presentation as unstable CAD (adjusted odds ratio [OR]=1.07, 95% CI 1.05-1.10, P, for each 20-point increase in the score). Coronary stenoses with 75% of lumen obstruction mediated almost all the increased risk related to the atherosclerotic burden for presentation as unstable CAD (adjusted OR=1.08, 95% CI 1.05-1.12, P). Conclusions: The present study showed that a higher coronary atherosclerotic burden is independently associated with increased risk of 1-year mortality in patients with stable and unstable CAD after PCI. The increased atherosclerotic burden is an independent correlate of presentation as unstable angina and the majority of risk for presentation as unstable angina is mediated by coronary stenoses with lumen narrowing of 75%.

BACKGROUND Transition from silent to clinically-overt coronary artery disease (CAD) is mostly related to the degree and speed of coronary obstruction leading to various degrees of myocardial ischemia. Rupture (or fissuring) of thin-cap atheromas with superimposition of thrombotic material is considered to be the underlying mechanism of acute coronary syndromes (ACS) in most, but not in all patients with CAD. Earlier serial angiographic studies showed that coronary occlusions resulting in ACS occur at the site of non-severe coronary artery stenoses in majority of patients. These studies supported the notion that mild to moderate coronary stenoses portend a higher risk for ACS than more severe stenoses which tend to remain unchanged. Recent studies in more contemporaneous series of patients disputed these views and showed that majority of acute myocardial infarctions occur at the site of significant stenoses and that intermediate coronary stenoses assessed by free-fractional reserve or intracoronary ultrasound show a very low event rate at long-term follow-up.

OBJECTIVES OF THE STUDY 1. To investigate the association of coronary atherosclerotic burden with mortality and other adverse events in a large series of consecutive patients with stable and unstable angina after percutaneous coronary intervention (PCI) 2. To compare angiographic coronary atherosclerotic burden in patients with stable and unstable angina and assessed the impact of coronary atherosclerotic burden on clinical presentation as unstable CAD

METHODS I Patients A consecutive series of 10 647 patients with stable (n=8149) and unstable (n=2498) CAD undergoing coronary angiography and PCI between March 2000 and December 2009. Angiographic confirmation of significant disease (at least one coronary stenosis with 50% lumen obstruction). Patients with non-st-segment elevation myocardial infarction (chest pain plus elevated fourth-generation assay cardiac troponin T level >0.03 μg/l), ST-segment elevation myocardial infarction, renal disease (serum creatinine level 2 mg/dl), acute infections or known malignancies were excluded. The study has been carried out in accordance with the Declaration of Helsinki and has been approved by the institutional ethics committee.

METHODS II Angiographic evaluation Angiographic data were analyzed in the Angiographic Core Laboratory. CAD was confirmed by the presence of coronary stenoses 50% lumen obstruction in at least one of the three main coronary arteries. Coronary atherosclerotic burden was estimated by using Gensini score. Gensini GG: Am J Cardiol 1983; 51:606

METHODS III Outcome measurement The primary outcome: Secondary outcome: All-cause mortality at 1 year after PCI procedure Cardiovascular mortality Nonfatal myocardial infarction Stroke, Target lesion revascularization Major adverse cardiac events (a composite of death, nonfatal myocardial infarction and target lesion revascularization) Presentation as unstable CAD Follow-up A phone interview at 1 month, a visit at 6 months and a phone interview at 12 months after PCI procedure.

RESULTS I 10647 patients: 8149 patients with stable CAD n=2498 patients with unstable CAD Gensini score: Gensini score quartiles: 131360 coronary segments analyzed <13 (1st quartile; n=2650 patients) 13 to <25 (2nd quartile; n=2611 patients) 25 to <53 (3rd quartile; n=2711 patients) >53 (4th quartile; n=2665 patients)

Main Baseline Characteristics RESULTS II Characteristic Quartiles of Gensini score P value Age (years) 1st (n = 2650) 66.0 [58.3; 73.0] 2nd (n = 2611) 61.1 [59.5; 74.1] 3rd (n = 2721) 67.1 [60.1; 74.2] 4th (n = 2665) 69.0 [61.5; 75.4] Women 739 (27.9) 647 (24.8) 575 (21.1) 416 (15.6) Arterial hypertension 1899 (71.7) 1930 (73.9) 198 (73.1) 1984 (74.4) 0.112 Hypercholesterolemia 1864 (70.3) 1865 (71.4) 2020 (74.2) 2128 (79.8) Diabetes 592 (22.3) 707 (27.1) 766 (28.2) 897 (33.7) Current smoker 420 (15.8) 347 (13.3) 319 (11.7) 293 (11.0) Prior myocardial infarction 733 (27.7) 738 (28.3) 921 (33.8) 1274 (47.8) Prior coronary artery bypass surgery 60 (2.3) 92 (3.5) 258 (9.5) 1317 (49.4) Presentation with unstable angina 518 (19.5) 582 (22.3) 699 (25.7) 699 (26.2) NYHA class 1 2 3 4 Glomerular filtration rate /ml/min) 1669 (62.9) 826 (31.2) 142 (5.4) 13 (0.5) 82.9 [64.1; 105.2] 1562 (59.8) 874 (33.5) 162 (6.2) 13 (0.5) 81.1 [63.0; 101.2] 1472 (54.1) 1028 (37.8) 205 (7.5) 16 (0.6) 81.5 [61.8; 101.9] 1222 (45.8) 1154 (43.3) 263 (9.9) 26 (1.0) 77.3 [58.5; 100.1] C-reactive protein (mg/l) 2.00 [0.89; 5.28] 1.90 [0.84; 4.86] 2.00 [0.88; 5.18] 2.35 [0.98; 6.2] Number of affected coronary arteries 1 961 (36.3) 431 (16.5) 259 (9.5) 71 (2.7) 2 925 (34.9) 875 (33.5) 716 (26.3) 321 (12.0) 3 764 (28.8) 1305 (50.0) 1746 (64.2) 2273 (85.3) Multivessel disease 1689 (63.7) 2180 (83.5) 2462 (90.5) 2594 (97.3)

RESULTS III Correlates of Presentation as Unstable CAD Independent Correlates of Presentation as Unstable CAD Variable Chisquare Adjusted odds ratio [95% confidence interval] P value C-reactive protein (for 5 mg/dl increase) 61.87 1.06 [1.05 1.08] Prior myocardial infarction 27.56 0.74 [0.66 0.83] Gensini score (for 20 points increase in severity) 26.85 1.07 [1.05 1.10] Female sex 13.33 1.25 [1.11 1.41] Current smoking 11.69 1.29 [1.11 1.49] Prior coronary artery bypass surgery 7.70 0.78 [0.66 0.93] Stenoses 75% were entered into the model this parameter (OR=1.08 [1.05 1.12], P; chi-square =20.30) but not Gensini score (OR=1.02 [0.99 1.06], P=0.210) predicted presentation as unstable CAD.

Clinical outcome RESULTS IV Characteristic Quartiles of Gensini score P value* 1st (n = 2650) 2nd (n = 2611) 3rd (n = 2721) 4th (n = 2665) All-cause mortality 41 (1.6) 42 (1.7) 83 (3.1) 129 (5.0) Cardiac mortality 24 (1.0) 24 (1.0) 60 (2.3) 81 (3.2) Nonfatal myocardial infarction 37(1.4) 67 (2.6) 95 (3.5) 120 (4.6) Stroke 6 (0.2) 13 (0.5) 16 (0.6) 16 (0.6) 0.155 Target lesion revascularization 304 (11.8) 416 (16.4) 615 (23.7) 611 (24.3) Major adverse cardiac events 366 (14.1) 492 (19.2) 732 (27.6) 775 (30.0) Data are Kaplan-Meier estimates. * calculated with log-rank test.

Probability of mortality (%) 10.0 8.0 6.0 4.0 2.0 0 P RESULTS V Kaplan-Meier Curves of All-Cause Mortality According to Gensini Score Quartiles 5.0% 3.1% 1.7% 1.6% 0 2 4 6 8 10 12 Patients at risk Months 4th quartile 2665 2567 2527 2502 2441 2413 2370 3rd quartile 2721 2649 2611 2591 2552 2535 2509 2nd quartile 2611 2571 2554 2541 2506 2486 2459 1st quartile 2650 2602 2593 2580 2531 2513 2481

RESULTS VI Kaplan-Meier Estimates of 1-Year Mortality in Patients with Stable and Unstable CAD Probability of mortality (%) 10.0 8.0 6.0 4.0 2.0 0 P 1.7 1.6 3.1 3.6 1 2 3 4 Gensini score quartiles Stable CAD P 1.0 2.0 3.3 8.8 1 2 3 4 Gensini score quartiles Unstable CAD

RESULTS VII Independent Correlates of 1-Year Mortality Variable Adjusted hazard ratio [95% confidence interval] P value Age (for 10-year increase in age) Gensini score (for 20 points increase in severity) Diabetes NYHA class (for 1 class increase in severity) 1.25 [1.04 1.51 1.08 [1.02 1.14] 1.56 [1.19 2.05] 1.45 [1.21 1.73] 0.018 0.007 0.002 Prior coronary artery bypass surgery Glomerular filtration rate (for 10 ml/min decrease) 0.63 [0.41 0.97] 1.20 [1.11 1.30] 0.034 C-reactive protein (for 5 mg/dl increase in concentration) 1.04 [1.03 1.06] Left ventricular ejection fraction (for 10% decrease) 1.44 [1.29 1.59]

CONCLUSIONS 1. A higher coronary atherosclerotic burden is independently associated with increased risk of 1-year mortality in patients with stable and unstable CAD after PCI. 2. The increased atherosclerotic burden is an independent correlate of presentation as unstable angina and the majority of risk for presentation as unstable angina is mediated by coronary stenoses with lumen narrowing of 75%.